| 摘要 |
The present invention relates to the use of GMFB as a biomarker for the early diagnosis and disease course progression of diabetic retinopathy, the use of GMFB as a therapeutic target for diabetic retinopathy, a GMFB interference agent and the use of GMFB interference agent. Compared with the prior art, the present invention confirms that in STZ-induced Type I diabetes (TIDM) rats, the GMFB content in the vitreous body is significantly increased at the early stage of the disease. First confirming that the GMFB content is decreased gradually, with the condition progression of DR which can be dynamically detected; and first confirming that interference to the GMFB expression of a DR rat can protect the visual function. First confirming that the GMFB mechanism mediates retinal degeneration, comprising causing a decrease in glutamine synthetase of Muller cells, leading to the death of ganglion cells, and inducing autophagy of photoreceptor cells toe. |
